Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis

Experimental data suggest that glioblastoma cells expressing the stem cell marker CD133 play a major role in radiochemoresistance and tumor aggressiveness. To date, however, there is no clinical evidence that the fraction of CD133‐positive cells in glioblastoma that recurs after radiochemotherapy may be relevant for prognosis.

[1]  L. Ricci-Vitiani,et al.  Tumorigenic Potential of Olfactory Bulb-Derived Human Adult Neural Stem Cells Associates with Activation of TERT and NOTCH1 , 2009, PloS one.

[2]  Tao Song,et al.  Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients , 2008, Journal of experimental & clinical cancer research : CR.

[3]  L. Ricci-Vitiani,et al.  Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[4]  Dong-Sup Lee,et al.  Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas , 2008, Laboratory Investigation.

[5]  U. Bogdahn,et al.  CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors , 2008, Brain pathology.

[6]  S. Kesari,et al.  Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas , 2008, Nature Clinical Practice Oncology.

[7]  L. Ricci-Vitiani,et al.  Mesenchymal differentiation of glioblastoma stem cells , 2008, Cell Death and Differentiation.

[8]  D. Gisselsson,et al.  Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma , 2008, PloS one.

[9]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[10]  A. Shervington,et al.  Expression of Multidrug Resistance Genes in Normal and Cancer Stem Cells , 2008, Cancer investigation.

[11]  P. Lichter,et al.  Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients , 2008, Clinical Cancer Research.

[12]  S. Kang,et al.  Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. , 2007, Stem cells and development.

[13]  R. Raedt,et al.  Endothelial Outgrowth Cells Are Not Derived From CD133+ Cells or CD45+ Hematopoietic Precursors , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[15]  Xiaofeng Yang,et al.  Most C6 cells are cancer stem cells: evidence from clonal and population analyses. , 2007, Cancer research.

[16]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[17]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[18]  U. Rutishauser,et al.  Use of polysialic acid in repair of the central nervous system , 2006, Proceedings of the National Academy of Sciences.

[19]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[20]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H Straatman,et al.  Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines , 2006, Oncogene.

[22]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[23]  H. Kettenmann,et al.  Glioblastoma-Induced Attraction of Endogenous Neural Precursor Cells Is Associated with Improved Survival , 2005, The Journal of Neuroscience.

[24]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[25]  F. DiMeco,et al.  Erratum: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma (Cancer Research (October 2004) 64 (7011-7021) , 2004 .

[26]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[27]  D. Wion,et al.  Development of gliomas: potential role of asymmetrical cell division of neural stem cells. , 2004, The Lancet. Oncology.

[28]  R. Mirimanoff,et al.  Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Ribatti.  The involvement of endothelial progenitor cells in tumor angiogenesis , 2004, Journal of cellular and molecular medicine.

[30]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[31]  R. Pallini,et al.  Glioblastoma induces vascular endothelial cells to express telomerase in vitro. , 2003, Cancer research.

[32]  G. Dewald,et al.  A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. , 2002, The American journal of pathology.

[33]  G. Fuller.  Pathology and Genetics of Tumours of the Nervous System (World Health Organization Classification of Tumours). , 2001 .

[34]  P. Black,et al.  Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[36]  C. James,et al.  Clonal genomic alterations in glioma malignancy stages. , 1988, Cancer research.